# Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

> **NCT01199822** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 16 (actual)

## Conditions studied

- Malignancy
- Metastasis

## Interventions

- **BIOLOGICAL:** Olaratumab

## Key facts

- **NCT ID:** NCT01199822
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199822, "Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01199822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*